Very few shares have traded hands since the completion of the clinical phase of the current trial. July’s volume was 4 times lower than the monthly volume during Jan to Mar. We might see a bit of a ramp up in trading activity towards the end of October but it looks like current investors aren’t willing to part with any of their holding at the current bid and those on the sidelines are happy to sit it out until November.
